 Home > Active Ingredient News > Immunology News > The first IgA nephropathy (IgAN) treatment!

The first IgA nephropathy (IgAN) treatment!

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

vyvanse drug test

addyi drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Kidney (Image source: thehealthsite.
com)

News on April 28, 2021 /bioon.
com" target="_blank">/ --Swedish biopharmaceutical company Calliditas Therapeutics recently announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of Nefecon (budesonide) and granted priority review, which is a new type of budesonide Oral preparation, the drug is an IgA1 down-regulator, which treats IgA nephropathy (IgAN) by targeted down-regulation of IgA1.
bioon.
com/fda/" target="_blank">The FDA has designated the NDA’s "Prescription Drug User Fees Act" (PUDFA) target date as September 15, 2021.

bioon.
com" target="_blank">bioon.
com/fda/" target="_blank">FDA

If approved, Nefecon will become the first therapy specifically designed and approved for the treatment of IgAN, with disease correction potential.
After obtaining approval, Calliditas intends to commercialize Nefecon alone in the United States.

Nefecon will be the first therapy specifically designed and approved for the treatment of IgAN, with disease correction potential.

Renée Aguiar Lucander, CEO of Calliditas, said: "We are very excited to receive priority review, which reflects the significant unmet medical needs for IgAN treatment.
We look forward to working with the agency to obtain accelerated approval later this year.
So that we can provide the first approved drug for IgAN patients.
"

jpg" target="_blank">

Nefecon: 2-step targeted release technology (click on the picture to see a larger picture)

Nefecon is a patented oral preparation containing a potent and well-known active substance-budesonide-for targeted release.
According to the main pathogenesis model, the preparation is designed to deliver drugs to the Peyer's patch in the lower small intestine where the disease originated.
Nefecon is derived from TARGIT technology, which allows substances to pass through the stomach and intestines without being absorbed, and can only be released in pulses when they reach the lower part of the small intestine.

As shown in the large Phase 2b trial completed by Calliditas, the combination of dose and optimized release profile is effective for IgAN patients.
In addition to effective local effects, another advantage of using this active substance is its low bioavailability, that is, approximately 90% of the active substance is inactivated in the liver before reaching the systemic circulation.
This means that high-concentration drugs can be applied locally where needed, but systemic exposure and side effects are very limited.

jpg" target="_blank">

Part A results of NefIgArd bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trial (click on the picture to see the larger picture)

bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">Clinical Trials

Calliditas is the only company that has obtained positive data in phase 2b and phase 3 randomized, double-blind, placebo-controlled bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trials of IgAN .
Both trials reached the primary and key secondary endpoints.

bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">Clinical Trials

The Nefecon NDA submission is based on the positive data from part A of the key phase 3 study of NefIgArd.
This is a randomized, double-blind, placebo-controlled, international multicenter study designed to evaluate the efficacy and safety of Nefecon and placebo in 200 adult IgAN patients.
As mentioned earlier, compared with placebo, the study reached the primary endpoint of reducing proteinuria and showed that eGFR was stable at 9 months.
The submitted information also includes clinical data from the NEFIGAN Phase 2 trial, which also reached the primary and secondary endpoints of the NefIgArd study.
Both trials showed that Nefecon was generally well tolerated, and the results of the two groups had similar safety.

Calliditas has applied for accelerated approval.
Accelerated approval is a new drug approval channel of the US bioon.
com/fda/" target="_blank">FDA , allowing drugs that have the potential to solve the unmet medical needs of major diseases to be approved based on a surrogate endpoint.
The surrogate endpoint of the key phase 3 trial NefIgArd is the reduction of proteinuria compared to placebo, which was based on the statistical framework of clinical research meta-analysis published by Thompson A et al.
in 2019 for interventions in IgAN patients in clinical studies.
stand by.
A confirmatory study designed to provide long-term kidney benefit data has been fully enrolled and is expected to be announced in early 2023.
()

bioon.
com/fda/" target="_blank">FDA

Original source: bioon.
com/fda/" target="_blank">FDA grants priority review for Nefecon, for patients with IgA nephropathy

bioon.
com/fda/" target="_blank">FDA

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.